Outcomes following synchronous liver resection, cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal liver and peritoneal metastases: A bi-institutional study.


Journal

Surgical oncology
ISSN: 1879-3320
Titre abrégé: Surg Oncol
Pays: Netherlands
ID NLM: 9208188

Informations de publication

Date de publication:
Jun 2021
Historique:
received: 27 01 2021
revised: 04 03 2021
accepted: 26 03 2021
pubmed: 12 4 2021
medline: 29 12 2021
entrez: 11 4 2021
Statut: ppublish

Résumé

Synchronous liver resection, cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal liver (CRLM) and peritoneal metastases (CRPM) has traditionally been contraindicated. However, latest practice promotes specialist, multidisciplinary-led consideration for select patients. This study aimed to evaluate the perioperative and oncological outcomes of synchronous resection in the management of CRLM and CRPM from two tertiary referral centres. This bi-institutional, retrospective, cohort study included patients undergoing simultaneous liver resection, CRS and HIPEC for metastatic colorectal cancer from 2013 to 2020. Patients treated with ablative liver techniques, staged operative approaches and extra abdominal disease were excluded. Overall survival (OS) and disease-free survival (DFS) rates were assessed. Univariate and multivariate analyses identified variables associated with survival and major morbidity (Clavien-Dindo grade III/IV). Twenty-three patients were included. The median peritoneal carcinomatosis index (PCI) was 9 (range 0-22). There were two major liver resections and 21 minor resections. CC-0 resections were achieved in all patients. Major morbidity occurred in 7 patients. There were no deaths at 90 days. PCI was independently associated with morbidity (p = 0.04). PCI >10 (p = 0.069), major morbidity (p = 0.083) and presence of KRAS mutation (p = 0.052) approached significance for poor OS. Median follow up was 21 months (4-54 months). Median OS was 37 months, 3-year survival 54%, and median DFS 18 months. Synchronous liver resection, cytoreductive surgery and HIPEC is feasible in selected patients with low-volume CRPM and CRLM. Increasing PCI is associated with postoperative major morbidity, and should be considered during operative planning.

Identifiants

pubmed: 33839444
pii: S0960-7404(21)00042-6
doi: 10.1016/j.suronc.2021.101553
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

101553

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Auteurs

Michael P Flood (MP)

Peter MacCallum Cancer Centre, Department of Surgical Oncology, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Australia. Electronic address: Michael.flood@petermac.org.

Peadar S Waters (PS)

Peter MacCallum Cancer Centre, Department of Surgical Oncology, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Australia.

Michael E Kelly (ME)

National Centre for Peritoneal Malignancy, Mater Misericordiae University Hospital, Ireland; Department of Hepatobiliary Surgery, Mater Misericordiae University Hospital, Ireland.

Conor Shields (C)

National Centre for Peritoneal Malignancy, Mater Misericordiae University Hospital, Ireland.

John Conneely (J)

Department of Hepatobiliary Surgery, Mater Misericordiae University Hospital, Ireland.

Robert Ramsay (R)

Peter MacCallum Cancer Centre, Department of Surgical Oncology, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Australia.

Michael Michael (M)

Sir Peter MacCallum Department of Oncology, University of Melbourne, Australia; Peter MacCallum Cancer Centre, Department of Medical Oncology, Australia.

Benjamin Loveday (B)

Peter MacCallum Cancer Centre, Department of Surgical Oncology, Australia; Department of Surgery, University of Auckland, New Zealand.

Satish K Warrier (SK)

Peter MacCallum Cancer Centre, Department of Surgical Oncology, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Australia.

Jurgen Mulsow (J)

National Centre for Peritoneal Malignancy, Mater Misericordiae University Hospital, Ireland.

Alexander G Heriot (AG)

Peter MacCallum Cancer Centre, Department of Surgical Oncology, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH